Al-Khatib, S.M., LaPointe, N.M., Kramer, J.M., et al. (2003). What clinicians should know about QT interval. Journal of the American Medical Association, 289, 2120–2127.
Anderson, M.E., Al-Khatib, S.M., Roden, D.M., et al. (2002). Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. American Heart Journal, 144, 769–781.
Auret, K., Roger Goucke, C., Ilett, K.F., et al. (2006). Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring, 28, 359–366.
Centeno, C. & Vara, F. (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of Pain Palliative Care Pharmacotherapy, 19(2), 7–12.
Derby, S., Chin, J., & Portenoy, R.K. (1998). Systemic opioid therapy for chronic cancer pain: Practical guidelines for converting drugs and routes of adminsistration. CNS Drugs, 9, 99–109.
Drug Facts and Comparisons. (2007), p. 1082. St. Louis: Wolters-Kluwer Health.
Dyer, K.R. & White, J.M. (1997). Patterns of symptoms complaints in methadone maintenance patients. Addiction, 92, 1445–1455.
Ehret, G.B., Voide, C., Gex-Fabry, M., et al. (2006). Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Archives of Internal Medicine, 166, 1280–1287.
Fitzgibbon, D.R. & Ready, L.B. (1997). Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain, 73, 259–261.
Garson, A. (1993). How to measure the QT interval—What is normal. American Journal of Cardiology, 72, 14B–16B.
Kornick, C.A., Kilborn, M.J., Santiago-Palma, J., et al. (2003). QTc interval prolongation associated with intravenous methadone. Pain, 105, 499–506.
Krantz, M.J. & Mehler, P.S. (2006) QTc prolongation: Methadone's efficacy-safety paradox. Lancet, 368, 556–557.
Lawlor, P.G., Turner, K.S., Hanson, J., et al. (1998). Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer, 82, 1167–1173.
Makin, M.K. (2000). Subcutaneous methadone in terminally-ill patients [letter]. Journal of Pain and Symptom Management, 19, 237–238.
Manfredi, P.L., Borsook, D., Chandler, S.W., et al. (1997). Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations. Pain, 70, 99–101.
Manfredi, P.L. & Houde, R.W. (2003). Prescribing methadone, a unique analgesic. Journal of Supportive Oncology, 1, 216–220.
Mathew, P. & Storey, P. (1999). Subcutaneous methadone in terminally ill patients: Manageable local toxicity. Journal of Pain and Symptom Management, 18, 49–52.
Mercadante, S., Casuccio, A., & Calderone, L. (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology, 17, 1–6.
Morley, J.S. & Makin, M.K. (1998). The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews, 5, 51–58.
Moss, A.J., Zareba, W., Benhorin, J., et al. (2001). ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: Task force summary. A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Annals of Noninvasive Electrocardiology, 6, 333–341.
Payne, R. & Inturrisi, C.E. (1985). CSF distribution of morphine, methadone and sucrose after intrathecal injection. Life Sciences, 37, 1137–1144.
Ripamonti, C., De Conno, F., Groff, L., et al. (1998). Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. Annals of Oncology, 9, 79–83.
Roden, D.M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350, 1013–1022.
Santiago-Palma, J., Khojainova, N., Kornick, C., et al. (2001). Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer, 92, 1919–1925.
Sekine, R., Eugenia, A.M.T., Coyle, N., et al. (2007). The successful use of parenteral methadone in a patient with a prolonged QTc interval. Journal of Pain and Symptom Management, 34, 566–569.
Shaiova, L. (2006). The role of methadone in the treatment of moderate to severe cancer pain. Supportive Cancer Therapy, 2, 1–5.